Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) EBIT (2016 - 2025)

Historic EBIT for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $54.9 million.

  • Ligand Pharmaceuticals' EBIT rose 164772.51% to $54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year increase of 20731.92%. This contributed to the annual value of -$22.6 million for FY2024, which is 28929.83% down from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported EBIT of $54.9 million as of Q3 2025, which was up 164772.51% from $8.4 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' EBIT registered a high of $54.9 million during Q3 2025, and its lowest value of -$36.2 million during Q1 2025.
  • Moreover, its 5-year median value for EBIT was $3.1 million (2024), whereas its average is $6.5 million.
  • Within the past 5 years, the most significant YoY rise in Ligand Pharmaceuticals' EBIT was 164772.51% (2025), while the steepest drop was 131204.82% (2025).
  • Over the past 5 years, Ligand Pharmaceuticals' EBIT (Quarter) stood at $37.7 million in 2021, then plummeted by 153.33% to -$20.1 million in 2022, then skyrocketed by 83.29% to -$3.4 million in 2023, then tumbled by 186.99% to -$9.6 million in 2024, then skyrocketed by 670.0% to $54.9 million in 2025.
  • Its EBIT stands at $54.9 million for Q3 2025, versus $8.4 million for Q2 2025 and -$36.2 million for Q1 2025.